RU2738114C2 - Пероральные фармацевтические композиции никотинамида - Google Patents

Пероральные фармацевтические композиции никотинамида Download PDF

Info

Publication number
RU2738114C2
RU2738114C2 RU2018137323A RU2018137323A RU2738114C2 RU 2738114 C2 RU2738114 C2 RU 2738114C2 RU 2018137323 A RU2018137323 A RU 2018137323A RU 2018137323 A RU2018137323 A RU 2018137323A RU 2738114 C2 RU2738114 C2 RU 2738114C2
Authority
RU
Russia
Prior art keywords
nicotinamide
minitablets
release
mesalazine
delayed
Prior art date
Application number
RU2018137323A
Other languages
English (en)
Russian (ru)
Other versions
RU2018137323A (ru
RU2018137323A3 (cg-RX-API-DMAC7.html
Inventor
Альфред Чи Ех ЛИАН
Венкатарамана ДИНГАРИ
Original Assignee
Конарис Рисёрч Инститьют Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Конарис Рисёрч Инститьют Аг filed Critical Конарис Рисёрч Инститьют Аг
Publication of RU2018137323A publication Critical patent/RU2018137323A/ru
Publication of RU2018137323A3 publication Critical patent/RU2018137323A3/ru
Application granted granted Critical
Publication of RU2738114C2 publication Critical patent/RU2738114C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018137323A 2016-04-19 2017-04-18 Пероральные фармацевтические композиции никотинамида RU2738114C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324415P 2016-04-19 2016-04-19
US62/324,415 2016-04-19
PCT/US2017/028063 WO2017184563A1 (en) 2016-04-19 2017-04-18 Oral pharmaceutical compositions of nicotinamide

Publications (3)

Publication Number Publication Date
RU2018137323A RU2018137323A (ru) 2020-05-19
RU2018137323A3 RU2018137323A3 (cg-RX-API-DMAC7.html) 2020-07-13
RU2738114C2 true RU2738114C2 (ru) 2020-12-08

Family

ID=59227843

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018137323A RU2738114C2 (ru) 2016-04-19 2017-04-18 Пероральные фармацевтические композиции никотинамида

Country Status (13)

Country Link
US (1) US11622938B2 (cg-RX-API-DMAC7.html)
EP (1) EP3445360B1 (cg-RX-API-DMAC7.html)
JP (1) JP7021108B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180135020A (cg-RX-API-DMAC7.html)
CN (1) CN109152772B (cg-RX-API-DMAC7.html)
AR (1) AR108233A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017252407A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018071363A2 (cg-RX-API-DMAC7.html)
CA (1) CA3021066C (cg-RX-API-DMAC7.html)
ES (1) ES2848575T3 (cg-RX-API-DMAC7.html)
RU (1) RU2738114C2 (cg-RX-API-DMAC7.html)
TW (1) TW201739455A (cg-RX-API-DMAC7.html)
WO (1) WO2017184563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408251SA (en) 2012-06-15 2015-01-29 Conaris Res Inst Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
CN105813644B (zh) 2013-12-13 2020-07-10 康纳里斯研究院股份公司 用于有益地影响肠道微生物丛和/或治疗胃肠道炎症的药物组合物
ES2788866T3 (es) 2013-12-13 2020-10-23 Conaris Res Institute Ag Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida para su uso en influir beneficiosamente en los niveles de lípidos en sangre mediante la modificación de la microbiota intestinal
US20210236519A1 (en) * 2020-01-30 2021-08-05 Atoz Pharmaceuticals Pvt Ltd Controlled release dosage forms of 5-aminosalicylic acid and process thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022096A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
WO2004066910A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2013186355A1 (en) * 2012-06-15 2013-12-19 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
WO2015086843A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
WO2015086838A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791458A (fr) 1972-07-31 1973-05-16 Merck & Co Inc Produit microencapsule
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
BR9408581A (pt) 1994-06-02 1997-08-26 Dan Riga Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
EP1248599B1 (de) * 2001-01-31 2007-12-05 Evonik Röhm GmbH Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
AU2006206423A1 (en) * 2005-01-21 2006-07-27 Pharmanova Inc. Pharmaceutical formulations and methods of use
EP1935422A1 (en) 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
EP2276491A4 (en) 2008-04-25 2011-08-17 Karolinska Inst Innovations Ab NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME
WO2010010579A1 (en) 2008-07-19 2010-01-28 Lupin Limited Multiple unit dosage form of niacin
WO2010077908A1 (en) 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Oral formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
EP2822542A1 (en) 2012-03-07 2015-01-14 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US20150164920A1 (en) 2012-03-30 2015-06-18 Laboratorios Del Dr. Esteve S.A. Controlled release formulation comprising mesalamine
US20140178468A1 (en) 2012-12-24 2014-06-26 Ranbaxy Laboratories Limited Multiparticulate extended-release composition of mesalamine
JP6294457B2 (ja) 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
ES2785399T3 (es) 2013-06-14 2020-10-06 Conaris Res Institute Ag Formulación de nicotinamida de liberación prolongada
US20170143743A1 (en) * 2014-06-16 2017-05-25 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
US20160045442A1 (en) 2014-08-13 2016-02-18 Cadila Healthcare Limited Stable pharmaceutical compositions of mesalamine
CN104257669A (zh) 2014-09-25 2015-01-07 合肥平光制药有限公司 一种用于向肠道递送水杨酸类药物的口服给药组合物
KR102381586B1 (ko) 2016-04-19 2022-04-04 훼링 비.브이. 메살라진의 경구용 약제학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022096A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
WO2004066910A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2013186355A1 (en) * 2012-06-15 2013-12-19 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
WO2015086843A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
WO2015086838A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Martin Korber et al. Enteric Polymers as Acidifiers for the pH-independent Sustained Delivery of a Weakly Basic Drug Salt From Coated Pellets, Eur J Pharm Biopharm. 2011 Aug; 78(3):447-54, найдено онлайн, найдено в Интернете: PMID: 21443950 DOI: 10.1016/j.ejpb.2011.03.018. *

Also Published As

Publication number Publication date
RU2018137323A (ru) 2020-05-19
EP3445360A1 (en) 2019-02-27
EP3445360B1 (en) 2020-11-11
ES2848575T3 (es) 2021-08-10
AR108233A1 (es) 2018-08-01
JP7021108B2 (ja) 2022-02-16
CA3021066C (en) 2024-04-09
JP2019513801A (ja) 2019-05-30
TW201739455A (zh) 2017-11-16
CN109152772B (zh) 2021-09-28
RU2018137323A3 (cg-RX-API-DMAC7.html) 2020-07-13
CA3021066A1 (en) 2017-10-26
US11622938B2 (en) 2023-04-11
BR112018071363A2 (pt) 2019-02-05
KR20180135020A (ko) 2018-12-19
WO2017184563A1 (en) 2017-10-26
CN109152772A (zh) 2019-01-04
AU2017252407A1 (en) 2018-11-01
US20200155461A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
RU2744576C2 (ru) Пероральные фармацевтические композиции месалазина
JP6434429B2 (ja) デフェラシロクスの経口製剤
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
JP2004521910A (ja) トラマドール系薬剤
RU2738114C2 (ru) Пероральные фармацевтические композиции никотинамида
JP2021152050A (ja) フマル酸ジメチルを含む医薬ビーズ製剤
WO2014174387A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
EP3796908A1 (en) Controlled release propiverine formulations
US20090186087A1 (en) Enteric sustained-release coated core and pharmaceutical dosage form and method for manufacturing the same
JP2013536832A (ja) ミルナシプランの制御放出医薬組成物
ZA200608190B (en) Controleld release dosage for GABA receptor antagonist
HK40005191B (en) Oral pharmaceutical compositions of nicotinamide
HK40005191A (en) Oral pharmaceutical compositions of nicotinamide